Sign up now!

If you'd like to learn more about what connecting with Diaceutics can do for you, click here to schedule a meeting.

To be part of the DXRX community and receive further marketing communications from us, please sign up via the form below.

Sign Up

This Ovarian Cancer Awareness Month our upcoming campaign aims to raise clinical awareness about the importance of biomarker testing in the diagnosis and treatment of advanced ovarian cancer.

Biomarkers play a critical role in identifying personalized treatment options and improving patient outcomes

*By submitting your information, you understand and agree to the DXRX User Terms. DXRX provides access to precision medicine content. A personal username and password to access DXRX will be provided separately by email. For details on how we process your personal data, see our Privacy Statement.

Background & Objectives
The Collaboration aims to understand what impact the new EU IVD regulation will have on the daily routines of EU4 (France, Germany, Italy, Spain) medium/large diagnostic laboratories using LDT/RUO tests for both IHC and molecular testing, as well as the challenges faced to be fully compliant. The final purpose of the Collaboration is to gain real-world insights from different territories to better understand the current situation and accompanying challenges to ultimately benefit patient care.

Collaboration Requirements, Benefits & Outcomes
The information above will help the understanding of how laboratories are planning to become compliant with the CE-IVD regulation and identify the challenges being encountered. This will allow Diaceutics to design strategies that better support patient testing and treatment.

Selection of the participants
Predetermined criteria will be used to identify participants eligible for this Collaboration. Eligibility will be determined by IHC and molecular test offerings, LDT/RUO test status and average sample volume.

Collaboration steps and deliverables
This Collaboration should be completed within 10 days of receipt of the email confirming your participation.

Should you meet the predetermined requirements in the three screening questions, you will be given access to the 10 minute survey, after which Diaceutics may request a 30 minute phone interview.

The Collaboration is implemented and sponsored by Diaceutics.

Any information you disclose will be treated in the strictest confidence and the results of the research aggregated to provide an overall picture of attitudes to the areas being covered in this survey.

Only Diaceutics will be aware of your specific answers and your identity will not be revealed to any third party. The outputs of this research will be used to inform on strategies that can help in supporting laboratories and to improve patient treatment.

PAYMENT
Honoraria for your time will be paid by Diaceutics. Diaceutics will compensate you with an amount of 50 Euros upon completion of the full survey and with an amount of 75 Euros for the 30 mins interview that could follow completion of the survey.

Are you a clinical lab professional who wants to make a difference? Sign up for updates on our ovarian cancer campaign and more - and get inspired by opportunities to help.

Your sign up will include you among oncologists and lab teams to facilitate multi-stakeholder education/communication and guarantees you access to:

Our campaign strives to

JOIN THE CIRCLE

Stay Informed on Life-Saving Ovarian Cancer Initiatives!

Actionable data insights

Featured Lab Talks providing the lab with insights into the latest industry challenges and changes

Latest articles covering developments in new biomarkers, Companion Diagnostics and Precision Medicine

Featured collaborations – opportunities to work with other stakeholders in Precision Medicine to solve real-world testing challenges

Educate patients and healthcare providers on the value of biomarker testing

Promote early and accurate diagnosis through molecular and genetic screening